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ABSTRACT 
The objective of this study was to investigate differences in the pharmacokinetic patterns between pure drug and an optimized  formulation of 
fast dissolving tablets  of Simvastatin. The formulations were administered to 2 groups of white New Zealand rabbits (n=6) following cross over 
design pattern and the plasma levels were measured using LC-MS/MS method. Pharmacokinetic parameters were determined for each 
formulation. The comparison of the plasma time curves of the dosage forms showed that each dosage form caused significant differences in the 
drug plasma levels.  The highest mean Cmax value was observed for optimized fast dissolving tablets (68.33  0.42ng/ml) compared to  pure 
drug (27.72  0.31ng/ml). The mean time taken to peak plasma concentration for (Tmax) following administration of pure drug  was  11.53  
0.011hours, while it was 6.09  0.072 hour following administration of selected optimized fast dissolving tablets.The elimination rate constant 
(Kel) for pure drug and optimized fast dissolving tablets were found to be 0.58  0.012h
-1
and 0.53  0.014 h
-1
 respectively.  The absorption rate 
constant (Ka) for pure drug and optimized fast dissolving tablets were found to be 1.68  0.01h
-1
and 5.53  0.02h
-1
 respectively. The AUC0-
αvalues observed with optimized fast dissolving tablets686.1.2.07 nghr/ml in compared to pure drug values 191  1.43 nghr/ml. Thus, the 
results of pharmacokinetic studies indicated rapid and higher oral absorption of Simvastatin when administered as its fast dissolving tablets. 
Both Ka and AUC were markedly increased by fast dissolving tablets. 
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 INTRODUCTION 
Simvastatin (SIM), a crystalline compound, is practically 
insoluble in water and hence poorly absorbed from the GI 
tract . It is a potent and specific inhibitor of 3-hydroxy-3-
methyl-glutaryl coenzyme A (HMG CoA) reductase , which 
catalyzes the reduction of HMG CoA to mevalonate. Thus, 
simvastatin arrests a key step for cholesterol biosynthesis in 
the liver and is widely used in the treatment of 
hypercholesterolemia and dyslipidemia as an adjunct to diet. 
After oral administration, simvastatin is metabolized to its β-
dihydroxy acid form (simvastatin acid) by the cytochrome-
3A system in the liver, where it inhibits the rate-limiting step 
in cholesterol biosynthesis. This leads to up-regulation of 
low-density lipoprotein (LDL) receptors and an increase in 
catabolism of LDL cholesterol. Being a BCS Class II drug, it 
often shows dissolution rate-limited oral absorption and high 
variability in pharmacological effects. The major problem of 
Simvastatin  is its very low water solubility, which results 
into poor dissolution rate. The pharmacokinetic performance 
of Simvastatin fast dissolving tablets was studied in a 
comparison with that of pure drug in rabbits 4.   
Materials and Methods: The in vivo study of the optimized 
formulations  were performed as per the guidelines 
approved by the Committee for the Purpose of Control and 
Supervision of Experiments on Animals (CPCSEA), Ministry 
of social Justice and Empowerment, Government of India.  
Prior approval by Institutional animals ethics committee was 
obtained for conduction of experiments (Ref:VIPER /IAEC/I-
7/ 2017-2018, Dated 21-9-2017). Pure Simvastatin and 
optimized fast dissolving tablets were selected based on in-
vitro release studies and stability conditions were chosen as 
dosage forms for administration. 
Subject selection: The pharmacokinetic performance of 
Pure Simvastatin and optimized Simvastatin fast dissolving 
tablets were studied in a randomized crossover study design 
in rabbits. Twelve New Zealand healthy rabbits with a mean 
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age of 10±2 weeks and with a mean body weight of 3±0.2 kg 
were used in this study. Each group consisted of six rabbits 
(n=6) each and were subjected for overnight fasting, it was 
taken care that there was no stress on the animals. Rabbits 
were randomly divided into two groups for different 
sampling time and each group was housed in one cage. Food 
and water were available ad libitum at all times during the 
experiment7-8. The study was conducted in a crossover 
design with 2 weeks washout periods in between the two 
experiments. The animal dose of Simvastatin was calculated 
relevant to human dose by using the following formula5-6.The 
above dosage form was administered through gastric 
intubation method. 
Human dose of Simvastatin= 100 mg.  
    Animal dose = Human dose × Animal weight 
                                  Human weight 
                  = 20x3/70= 0.85 mg = 1mg 
Blood sampling: About 1 ml of blood samples were collected 
from the tracheal lobular vein of the rabbit using and the 
blood was stored in screw top heparinized plastic tubes, the 
sampling time for blood was done at  0 (before drug 
administration),  0.5, 1.0, 2.0, 3.0, 4.0 and 6.0 hrs after pure 
drug  administration and  at 0,1, 2, 4, 6, 8, 12, 16, 20, and 24 
hrs after administration of Simvastatin fast dissolving tablets. 
The plasma was immediately separated by aspiration after 
centrifugation at 4000 rpm for 5 minutes and frozen at -20 ºC 
until analyzed by LC-MS/MS method7-8. 
Determination of Pharmacokinetic Parameters: 
Various pharmacokinetic parameters such as peak plasma 
concentration (Cmax), time at which peak occurred (Tmax), 
area under the curve (AUC), elimination rate constant (Kel), 
biological half-life (t½) and mean residence time (MRT) were 
calculated using the noncompartmental pharmacokinetics 
data analysis software PK Solutions 2.0™(Summit Research 
Services, Montrose, CO, USA)9.The pharmacokinetic 
parameters of the tested formulations were statistically 
analyzed using paired sample’s t-test for normal distributed 
results of Cmax, Ka,Ke, MRT and AUC0-α value. All tests were 
performed at 0.001 level of significance10. 
 
 
Estimation of Simvastatinin plasma (LC-MS/MS method11: 
Chromatographic conditions 
A summary of the chromatographic and mass spectrometric conditions is as follows: 
UPLC                                   :WATERS  
Mass spectrometer               : API 2000  
Ion source                             : Heated nebulizer 
Polarity                                   : Negative Detection ions            
Simvastatin   : 240.2 * amu (parent), 196.0* amu (product) 
d3-Simvastatin            : 244.2* amu (parent), 200.2  amu (product) 
Column                                   : Phenomenax, synergi 4 µ Polar- RP80 A, 4.6x75mm 
Column oven temperature     : 35° C 
Peltier temperature                 : 10°C 
Mobile phase                          : Ammonium formate: Acetonitrile (30:70)  
 Flow rate                                 : 1ml/min. 
Volume of injection                   :  10 µ L 
Retention time                         : Simvastatin-  0.5  to 1.20 minutes 
                                                   : ISTD-0.5 to 1.20 minutes 
Run time                                  : 2.00 minutes 
 
Preparation of working standard solutions: 
1. Preparation of Simvastatin standard stock solution:  
Simvastatin working standard equivalent to 5 mg 
Simvastatin was accurately weighed and transferred into a 5 
ml volumetric flask and dissolved in methanol. The solution 
was made up to the volume with methanol. The 
concentration of resulting solution was calculated by 
considering the purity of Simvastatin. The solutions were 
labeled and stored in a cold store at 2-8°C.  
 
 
2. Preparation of internal   standard stock solution: 
0.005 g of d3-Simvastatinwas weighed accurately and 
transferred in to a 5 ml volumetric flask and dissolved in 
methanol. The solution was made up to the volume with 
methanol. The concentration of resulting solution was 
calculated by considering the purity of Simvastatin –d4 .  
The solutions were labeled and stored in a cold store at 2-
8°C. Stock solution was diluted with 60% Acetonitrile in 
water solution to get a concentration of 75.00µg/ml. 
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Calibration curve standards: 
1. Preparation of stock dilutions of standard Simvastatin  
solution: 
Stock solution of Simvastatin was diluted with 60% 
Acetonitrile in water solution to get a concentrations ranging 
from 1 to 140 µg/ml.  
2. Spiking of plasma for calibration curve standards: 
 Concentrations of Simvastatin ranging from 50 to 7000 
ng/ml were prepared with plasma and labeled them as CC1 
to CC8. The calibration curve standards were prepared 
freshly for each validation run.  
3. Extraction procedure 
Step 1: Blank, calibration curve standards and the subject 
samples were withdrawn from the deep freezer and allowed 
them to thaw. The thawed samples were vortexed to ensure 
complete mixing of contents. To 0.25 ml of plasma sample in 
a ria vial, 25ul of d3-Simvastatinstandard (75µg/ml) was 
added. To plasma blank, 25 ul of 60% Acetonitrile in water 
solution was added and vortexed the samples to ensure 
complete mixing of contents.  
Step 2:  Add 2.5 ml of tertitary butyl methyl  ether, place on a 
shaker for 15 minutes and centrifuge for 10 minutes at 
4000rpm at 20OC. Transfer  supernatant (organic layer ) into 
the another rial vial. Evaporate this layer under a stream of 
nitrogen at 45 OC. The residue was reconstituted with 0.5 ml 
of mobile phase and vortexed.   The samples were 
transferred in to auto-injector vials and loaded the vials in to 
auto sampler. 10  ul of sample was injected in to LC-MS/MS 
system. Analyte Concentrations of stock dilutions of standard 
Simvastatin solution with plasma were shown in Table 1.
 
 
Table 1:Analyte Concentrations of Stock Dilutions of Standard Simvastatin Solution with Plasma 
S.NO 
Sample 
Name 
Analyte 
Concentration 
(ng/ml) 
Analyte 
peak area 
IS Peak 
Area 
Area 
Ratio 
Calculated 
Concentration 
(ng/ml) 
Accuracy 
(%) 
1 
Plasma 
Blank 
0 0 0 0 N/A N/A 
2 Blank+ISTD 0 254 513643 0 N/A N/A 
3 CC1 50.05 3879 528938 0.01 50.407 100.71 
4 CC2 100.15 6997 506198 0.01 97.939 97.79 
5 CC3 250.300 17284 484351 0.04 258.119 103.12 
6 CC4 500.650 34646 504084 0.07 500.215 99.91 
7 CC5 1001.250 77371 577631 0.13 978.007 97.68 
8 CC6 2002.500 134349 520675 0.26 1887.085 94.24 
9 CC7 5006.250 345626 529110 0.65 4782.401 95.53 
10 CC8 7008.750 578109 544120 1.06 7780.670 111.01 
 
 
 
 
Figure 1: Calibration Curve for Estimation of 
Simvastatinin Plasma: 
 
 
4. Data processing 
The chromatograms were obtained by using the computer-
based Analyst 1.4.2 version software supplied by the 
Applied Biosystems, Canada. The concentrations of the 
unknown samples were calculated from the equation using 
regression analysis of spiked plasma calibration standard 
with 1/x2 as weighting factor.  y = mx + c; Where, y = Ratio 
of Simvastatin  peak area and ISTD peak area (analyte area 
/ ISTD area); x = Concentration of Simvastatin  ;m = Slope 
of the calibration curve; c = y-axis intercept value. Linear 
regression analysis equation of stock dilutions of standard 
Simvastatin  solution with plasma is, y = 0.000136x + 
0.000454. 
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RESULTS AND DISCUSSION: 
The in vivo experiments were conducted as per the protocol 
and procedure described earlier. Bioanalytical methods 
employed for the quantitative determination of drugs and 
their metabolites in biological matrix (plasma, urine, saliva, 
serum etc) play a significant role in evaluation and 
interpretation of pharmacokinetic data. For the successful 
conduct of pharmacokinetic study, the development of 
selective and sensitive bioanalytical methods plays an 
important role for the quantitative evaluation of drugs and 
their metabolites (analytes). The LC-MS/MS methods were 
highly sensitive and suitable for the detection of drug in 
plasma even in low concentrations. Calibration curves were 
constructed from blank sample (plasma sample processed 
without IS), blank+IS samples and eight point calibration 
standards for Simvastatin in plasma. Plasma concentrations 
of Simvastatin at different times were calculated and are 
shown in Table 2 and in Fig 2.Pharmacokinetic parameters 
such as absorption rate constant, elimination rate constant, 
half-life, AUC, and MRT were calculated from the plot of time 
versus plasma concentration and subjected to statistical 
analysis and the results were shown in Table 3.  
 
 
Table 2: Plasma Concentrations of Simvastatin following oral administration of Pure Simvastatin and optimized fast 
dissolving tablets 
Time  
(h) 
Plasma concentration 
(ng/ml) (Mean s.d) 
Pure drug Simvastatin    fast dissolving tablets  
0 0 0 
0.5 08.51 1.86 28.23 1.36 
1 11.351.74 36.441.78 
1.5 12.511.52 42.201.56 
2 14.611.14 45.241.24 
3 16.751.64 49.621.12 
4 18.811.35 54.121.65 
5 19.621.43 61.181.67 
6 21.931.24 68.331.85 
8 22.761.43 62.151.72 
10 24.901.24 57.421.22 
12 27.721.27 49.23 1.36 
14 24.641.36 42.201.43 
16 21.961.53 35.241.64 
18 18.841.32 28.531.18 
20 15.921.21 23.121.62 
24 12.281.39 17.181.47 
 
FIGURE 2: Concentration-Time Curve of Simvastatin following oral administration of Pure Simvastatin and optimized 
fast dissolving tablets 
 
 
(-♦-)plasma Concentration -Time Curve of Simvastatin following pure drug  administration 
(-■-)plasma Concentration- Time Curve of Simvastatin following optimized fast dissolving tablets  administration 
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Table 3: Statistical Treatment of Pharmacokinetic Parameters (Mean  S.D.) of following oral administration of Pure 
Simvastatin and optimized fast dissolving tablets 
Pharmacokinetic parameter Pure Drug  
Optimized fast dissolving 
tablets 
Calculated value of ‘t’ 
Cmax (ng/ml) 27.72 0.31 68.33 0.42 26.70*** 
t1/2 (h)  11.53  0.011 6.09  0.072 40. 75*** 
Kel (h-1) 0.58 0.012 0.53 0.014 6.87*** 
Ka (h-1) 1.68 0.01 5.53 0.02 19.67*** 
AUC0-  (ng h/ml) 191 1.43 686.1.2.07 256.60*** 
Null hypothesis (Ho):There is no significant difference between the pharmacokinetic parameters of Simvastatin obtained with 
pure drug  and optimized fast dissolving tablets. Table value of ‘t’ with 10 DF at the 0.001 level is 4.587. 
Result: Ho is not accepted as the calculated ‘t’ value more than the table Value of‘t’ with 10 DF at 0.001 levels of significance. It 
was therefore concluded that there was significant difference between the pharmacokinetic parameters of obtained with pure 
drug  and optimized fast dissolving tablets. 
 
The results indicated that the parameters significantly 
differed following optimized fast dissolving tablets 
administration, compared to pure drug  administration. The 
highest mean Cmax value was observed for optimized fast 
dissolving tablets (68.33  0.42ng/ml) compared to  pure 
drug (27.72  0.31ng/ml). The mean time taken to peak 
plasma concentration for (Tmax) following administration of 
pure drug  was 11.53  0.011hours, while it was 6.09  0.072 
hour following administration of selected optimized fast 
dissolving  tablets. The elimination rate constant (Kel) for 
pure drug and optimized fast dissolving tablets were found to 
be 0.58  0.012h
-1
and 0.53  0.014 h
-1
 respectively.  The 
absorption rate constant (Ka) for pure drug and optimized 
fast dissolving tablets were found to be 1.68  0.01h
-1
and 
5.53  0.02h
-1
 respectively. The AUC0-αvalues observed with 
optimized fast dissolving tablets686.1.2.07 ng hr/ml in 
compared to pure drug values 191  1.43 ng hr/ml. Thus, the 
results of pharmacokinetic studies indicated rapid and higher 
oral absorption of Simvastatin when administered as its fast 
dissolving tablets. Both Ka and AUC were markedly increased 
by fast dissolving tablets. 
 
 
Figure 3: Chromatograms of reserve stock solution of Standard Simvastatin Solution with Plasma 
Sample Name:Plasma blank 
Simvastatin 
Mass(es):240.2/196.0amu 
Concentration: 0.000 ng/ml 
Calculated conc:N/A ng/ml 
Proc. Algorithm: Analyst classic 
Bunching factor:2 
Noise Threshold:10.00 
Area Threshold :100.00 
Num Smooths :10 
Sep .Width :0.20 
Sep. Height:0.01 
Exp .Peak Ratio:5.00 
Exp.Adj Ratio:4.00 
Exp .Val Ratio :3.00 
RT Window :30.0 
Expected RT:2.00 
Use Relative RT:False 
Int. Type:  No Peak  
Retention Time:0.00 
Area: 0 
Height:0 
Area Ratio:0.000 
Start Time:0.00 
End Time:0.00 
 
 
Sureh Babu et al        Journal of Drug Delivery &Therapeutics. 2019; 9(5):490-496 
ISSN: 2250-1177                                                                       [495]   CODEN (USA): JDDTAO 
Sample Name: Plasma blank- 
d3-Simvastatin 
Mass(es):244.2/200.2amu 
Concentration: N/A ng/ml 
Calculated conc: N/A ng/ml 
Proc.Algorithm: Analyst classic 
Bunching factor:1 
Noise Threshold:20.00 
Area Threshold :200.00 
NumSmooths :10 
Sep .Width: 0.20 
Sep. Height:0.01 
Exp .Peak Ratio: 5.00 
Exp.Adj Ratio: 4.00 
Exp .Val Ratio :3.00 
RT Window : 30.0 
Expected RT: 1.80 
Use Relative RT:False 
Int. Type:  Base To Base  
Retention Time:1.85 
Area:416 
Height:125 
Start Time:1.79 
End Time:1.90 
 
 
 
Figure 4: Chromatograms of Plasma blank and internal standard (d3-Simvastatin) 
Sample Name: Plasma blank+ISTD 
Mass(es): 240.2/196.0amu 
Concentration: 0.000 ng/ml 
Calculated conc:N/A ng/ml 
Proc.Algorithm: Analyst classic 
Bunching factor: 2 
Noise Threshold: 10.00 
Area Threshold :100.00 
NumSmooths :10 
Sep .Width: 0.20 
Sep. Height: 0.01 
Exp .Peak Ratio: 5.00 
Exp.Adj Ratio: 4.00 
Exp .Val Ratio :3.00 
RT Window :30.0 
Expected RT: 2.00 
Use Relative RT:False 
Int. Type:  No Peak  
Retention Time:0.00 
Area: 0 
Height: 0 
Area Ratio: 0.00 
Start Time:0.00 
End Time:0.00 
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Sample Name: Plasma 
blank+ISTD -d3-Simvastatin 
Mass(es): 244.2/200.2amu 
Concentration: 1.000 ng/ml 
Calculated conc:N/A ng/ml 
Proc.Algorithm: Analyst 
classic 
Bunching factor:1 
Noise Threshold:20.00 
Area Threshold :200.00 
NumSmooths :10 
Sep .Width:0.20 
Sep. Height:0.01 
Exp .Peak Ratio:5.00 
Exp.Adj Ratio:4.00 
Exp .Val Ratio :3.00 
RT Window :30.0 
Expected RT :0.89 
Use Relative RT:False 
Int. Type:  Base To Base  
Retention Time:0.97 
Area: 513643 
Height: 1.3e5+0.005 
Start Time:0.89 
End Time: 1.03 
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